Please login to the form below

Not currently logged in
Email:
Password:

gene-editing

This page shows the latest gene-editing news and features for those working in and with pharma, biotech and healthcare.

MaxCyte gets green light for solid tumour cell therapy

MaxCyte gets green light for solid tumour cell therapy

collaborations and licensing deals with academic and industrial partners, which now number 55 across “immuno-oncology, gene editing and regenerative medicine.”.

Latest news

  • AZ makes gene therapy move with 4DMT alliance AZ makes gene therapy move with 4DMT alliance

    AZ makes gene therapy move with 4DMT alliance. The new partnership will focus on creating an AAV for lung disease. ... have focused on RNA and oligonucleotide-based drugs to switch off the activity of problem genes and gene-editing using CRISPR technology

  • Abingworth raises $315m to expand hunt for promising biotechs Abingworth raises $315m to expand hunt for promising biotechs

    gene therapies have reinvigorated biotech’s access to venture funding and prompted a spate of public listings. ... Abingworth has shown it is prepared to back leading edge science, as witnessed by its participation in the first funding round for

  • Morning brief: New biotech launched, Merck and Moderna expand collaboration and more Morning brief: New biotech launched, Merck and Moderna expand collaboration and more

    Abcam launches takeover for gene-editing specialists Horizon Discovery. Abcam, a UK-based biotech research services firm launched a takeover bid for its neighbour and rival Horizon Discovery this week, but ... in the gene editing market.

  • ABPI explores the future of medicines ABPI explores the future of medicines

    Teaming up with INITION, the virtual reality production company, the experience includes the possibilities of gene editing and gene therapies along with 3D printing of medicine patches, which UK scientists are

  • Gilead study resurrects HIV eradication hope Gilead study resurrects HIV eradication hope

    Researchers are looking at other ways to eradicate HIV, including gene-editing techniques which focus on snipping HIV genetic material from cells or rendering immune cells resistant to entry by the

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • 30 women leaders in UK healthcare (part 3) 30 women leaders in UK healthcare (part 3)

    23. Dr Kathy Niakan, Developmental Biologist, The Francis Crick Institute. The last few years have seen a huge surge of interest in new gene editing tools that have enormous potential as ... The greatest excitement is reserved for CRISPR-Cas9 gene editing

  • Gene therapy Gene therapy

    the promise of gene therapy in the early nineties could not be remotely met. ... From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines,

  • Deal Watch March 2017 Deal Watch March 2017

    Editas Medicine has entered a strategic R&D alliance where Allergan has exclusive access to Editas’s CRISPR genome-editing programmes in ocular health, as well as options to license up ... 100. Editas. Allergan. R&D alliance. LCA10 and up to four other

  • Winning the war against cancer Winning the war against cancer

    areas such as the gene-editing CRISPR technology.

  • Deal Watch May 2016 Deal Watch May 2016

    disease late last year, Bayer announced another gene editing pact this month with ERS Genomics. ... 5, 200. Univ Pennsylvania/ Biogen. Licence. Gene editing and therapy using AAV vectors; $20m upfront, $62.5m in R&D funds, $77.5 -$137.5m m/s per programme

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Eric Rhodes becomes CEO of ERS Genomics Eric Rhodes becomes CEO of ERS Genomics

    In these roles, Rhodes was responsible for commercialising the company's genome editing technologies as well as driving its research and development. ... Biosciences. Foy said: “ With his deep understanding of the gene-editing landscape and extensive

  • Marc Becker joins CRISPR Therapeutics Marc Becker joins CRISPR Therapeutics

    Marc Becker joins CRISPR Therapeutics. He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    Training the next generation of biotech leaders. Cell and gene therapy is no longer science fiction. ... It’ s such a disruptive advancement – it’ s just incredible to think it has all been made feasible through advancements in gene editing.”.

  • Perspective on biotech

    Find out about:. The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics